- Home
- DMAC vs WILC Comparison
DMAC vs WILC Comparison
Compare DMAC & WILC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- WILC
- Stock Information
- Founded
- DMAC 2000
- WILC 1994
- Country
- DMAC United States
- WILC Israel
- Employees
- DMAC N/A
- WILC N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- WILC Food Distributors
- Sector
- DMAC Health Care
- WILC Consumer Discretionary
- Exchange
- DMAC Nasdaq
- WILC Nasdaq
- Market Cap
- DMAC 310.1M
- WILC 273.9M
- IPO Year
- DMAC N/A
- WILC 1997
- Fundamental
- Price
- DMAC $6.70
- WILC $21.20
- Analyst Decision
- DMAC Strong Buy
- WILC
- Analyst Count
- DMAC 3
- WILC 0
- Target Price
- DMAC $12.33
- WILC N/A
- AVG Volume (30 Days)
- DMAC 256.1K
- WILC 4.1K
- Earning Date
- DMAC 11-12-2025
- WILC 11-19-2025
- Dividend Yield
- DMAC N/A
- WILC 3.96%
- EPS Growth
- DMAC N/A
- WILC 130.51
- EPS
- DMAC N/A
- WILC 2.04
- Revenue
- DMAC N/A
- WILC $177,609,889.00
- Revenue This Year
- DMAC N/A
- WILC N/A
- Revenue Next Year
- DMAC N/A
- WILC N/A
- P/E Ratio
- DMAC N/A
- WILC $10.36
- Revenue Growth
- DMAC N/A
- WILC 9.73
- 52 Week Low
- DMAC $3.19
- WILC $11.10
- 52 Week High
- DMAC $7.49
- WILC $22.85
- Technical
- Relative Strength Index (RSI)
- DMAC 48.84
- WILC 58.22
- Support Level
- DMAC $6.50
- WILC $20.12
- Resistance Level
- DMAC $7.10
- WILC $20.42
- Average True Range (ATR)
- DMAC 0.29
- WILC 0.18
- MACD
- DMAC -0.03
- WILC 0.08
- Stochastic Oscillator
- DMAC 32.90
- WILC 100.00
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About WILC G. Willi-Food International Ltd.
G. Willi-Food International Ltd is a company engaged in high-quality, great-tasting kosher food products. The Company is engaged, directly and through subsidiaries, with one segment Import-export, marketing, and distribution of food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Dried Fruit, Nuts and Beans, and Other Products. Its brands include Willi-Food, Euro European Dairies, Donna Rozza, Manchow, Gold Frost, Tifeeret, The Chef Dish, Art Coffe, Mr. Chang, Muchi, Euro Butter, Euro Spread, Euro Cheese, Euro Cream, Euro Dessert, Euro Veg, Ha-Bulgaria, Gelato, and Emma.